ClinicalTrials.gg
CompletedNCT01274351Updated Sep 1, 2020Results posted

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

A Phase 2 interventional study of Nilotinib in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
21st of 66
112 · median 55
Started
2011
with 3 others
Phase 2
25 of 66
1 open now
Registered
26th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 21st largest by enrollment, is one of 4 that started in 2011, is one of 25 in phase 2, and was the 26th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The study was a local multicentric, open-label, non-randomized phase II study of nilotinib as a first line treatment in adult patients with newly-diagnosed Philadelphia chromosome-positive (Ph+) and chronic phase myeloid leukemia (CML-CP).

Read the detailed description

This was a multicenter, open-label, single-arm, phase 2 study of nilotinib as a frontline treatment for patients with Ph+ CMLCP. All patients received oral nilotinib 300 mg twice daily for a planned treatment duration of 24 months or until early discontinuation.

The primary efficacy end point was the cumulative rate of Major Molecular Response (MMR) in all participants by 12 months. Secondary efficacy end points included the rate of Complete Cytogenic Response (CCyR) at 6 and 12 months; cumulative rates of MMR up to 24 months; time to and durability of MMR; and cumulative rate of Complete Haematologic Response (CHR) by 12 months.

Patient evaluations, including hematologic assessments, were conducted every 15 days during the first 3 months, monthly until month 12, and then every 3 months until the end of the study (24 months). All efficacy analyses were performed in the intent-to treat population.

03

Conditions studied

  • Chronic Myelogenous Leukemia

Keywords

  • First line treatment
  • newly diagnosed
  • Philadelphia chromosome positive
  • Chronic Myelogenous Leukemia
  • Ph+
  • CML-CP
  • major molecular response
  • Social risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status 0, 1, or 2
  • First cytogenetic diagnosis of CML-CP with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations within 6 months. Standard conventional cytogenetic analysis must be performed.
  • Previously untreated for CML, except for hydroxyurea and/or anagrelide (except imatinib treatment for max. 31 days long)
  • Adequate end organ function with following laboratory criteria: total \< 1.5 x (ULN); (ALT) and aspartate aminotransferase (AST) \< 2.5 x upper limit of normal (ULN); creatinine \< 1.5 x upper limit of normal (ULN); serum amylase and lipase ≤ 1.5 x upper limit of normal (ULN); alkaline phosphatase ≤ 2.5 x upper limit of normal (ULN) unless considered tumor related
  • Serum potassium, magnesium, and phosphorus levels are equal or above the lower limit of normal prior to the first dose of study medication

Exclusion criteria

Exclusion Criteria:

  • Treatment with tyrosine kinase inhibitor(s) prior to study (in emergent cases where the patient requires disease management while awaiting study start, commercial supplies of imatinib at any dose may be prescribed to the patient but for no longer than 31 days in duration)
  • Known cytopathologically confirmed Central Nervous System CNS infiltration
  • Impaired cardiac function
  • Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection)
  • Acute or chronic liver, pancreatic or severe renal disease considered unrelated to disease
  • Patients with another primary except if the other primary malignancy is neither currently or requiring active intervention
  • History of significant congenital or acquired bleeding disorder unrelated to cancer
  • Previous radiotherapy to ≥25% of the bone marrow
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
  • Use of therapeutic coumarin derivatives (i.e. warfarin, acenocoumarol, phenprocoumon)
  • Patients actively receiving therapy with strong Cytochrome P450 3A4 isoenzyme () inhibitors (e.g, erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil)
  • Patients actively receiving therapy with medications that have the potential to prolong the and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Nilotinib

    administered orally at a dose of 300 mg twice daily for 24 months

    Drug: Nilotinib

Interventions

  • administered orally at a dose of 300 mg twice daily for 24 months

    Also known as: Tasigna, AMN107

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months

    Major Molecular Response (MMR) was defined as BCR-ABL1\^IS ≤0.1%, on the International Scale \[BCR-ABL1IS\]) by 12 months. BCR is the Breakpoint Cluster Region gene / BCR gene product and ABL is the Abelson proto-oncogene. BCR-ABL is the Fusion gene from BCR and ABL/Protein product from BCR-ABL. Participants who withdrew prematurely or those who failed to provide data for the study for other reasons were designated as premature withdrawal or inevaluable, respectively, and were included in the ITT analysis as non-responders.

    Time frame: 12 months

Secondary outcomes

  1. Percentage of Participants Who Achieved Major Molecular Response (MMR) up to 24 Months

    Major Molecular Response (MMR) was defined as BCR-ABL1\^IS ≤0.1%, on the International Scale \[BCR-ABL1IS\]) by 12 months. BCR is the Breakpoint Cluster Region gene / BCR gene product and ABL is the Abelson proto-oncogene. BCR-ABL is the Fusion gene from BCR and ABL/Protein product from BCR-ABL. Participants who withdrew prematurely or those who failed to provide data for the study for other reasons were designated as premature withdrawal or inevaluable, respectively, and were included in the ITT analysis as non-responders.

    Time frame: 3, 6, 9, 15, 18, 21 and 24 months

  2. Percentage of Participants With Complete Cytogenetic Response (CCyR) at Month 6 and 12

    CCyR rate is identified as the rate of patients who had 0% of Ph+ metaphase.

    Time frame: Month 6 and 12

  3. Percentage of Participants With Complete Hematologic Response (CHR) at Month 3, 6, 9, 12, 18 and 24

    A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved: WBC \<10 x 109/L, thrombocyte \<450 x 109/L, myelocyte + metamyelocyte \<%5 in blood, no sign of blast and promyelocyte in blood, basophil \<%5, and no sign of extramedullary involvement.

    Time frame: Month 3, 6, 9, 12, 18 and 24

  4. Time to Major Molecular Response (MMR)

    Time to MMR is defined as the time period from the date of first dose intake until the first documented MMR.

    Time frame: 24 months

  5. Duration of Major Molecular Response (MMR)

    MMR duration is defined as the time from the date of first documented MMR to the first time of the lost MMR, progression or death.

    Time frame: 24 months

07

Results

Posted Sep 1, 2020

Participant flow

A total of 112 participants were enrolled into the study from the 15 sites in Turkey.

Participant flow — Overall Study
MilestoneNilotinib
Started112
Completed92
Not completed20
Withdrew: Lost to follow-up1
Withdrew: Patient not compliant with the protocol1
Withdrew: Pregnancy1
Withdrew: Death2
Withdrew: Withdrawal by subject3
Withdrew: Adverse event8
Withdrew: Progression of disease3
Withdrew: Hospitalization1

Outcome measures

PrimaryPercentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months

Major Molecular Response (MMR) was defined as BCR-ABL1\^IS ≤0.1%, on the International Scale \[BCR-ABL1IS\]) by 12 months. BCR is the Breakpoint Cluster Region gene / BCR gene product and ABL is the Abelson proto-oncogene. BCR-ABL is the Fusion gene from BCR and ABL/Protein product from BCR-ABL. Participants who withdrew prematurely or those who failed to provide data for the study for other reasons were designated as premature withdrawal or inevaluable, respectively, and were included in the ITT analysis as non-responders.

Time frame:
12 months
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months
ParticipantsNilotinib
Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months74
SecondaryPercentage of Participants Who Achieved Major Molecular Response (MMR) up to 24 Months

Major Molecular Response (MMR) was defined as BCR-ABL1\^IS ≤0.1%, on the International Scale \[BCR-ABL1IS\]) by 12 months. BCR is the Breakpoint Cluster Region gene / BCR gene product and ABL is the Abelson proto-oncogene. BCR-ABL is the Fusion gene from BCR and ABL/Protein product from BCR-ABL. Participants who withdrew prematurely or those who failed to provide data for the study for other reasons were designated as premature withdrawal or inevaluable, respectively, and were included in the ITT analysis as non-responders.

Time frame:
3, 6, 9, 15, 18, 21 and 24 months
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieved Major Molecular Response (MMR) up to 24 Months
ParticipantsNilotinib
3 months28
6 months57
9 months67
15 months84
18 months92
21 months93
24 months93
SecondaryPercentage of Participants With Complete Cytogenetic Response (CCyR) at Month 6 and 12

CCyR rate is identified as the rate of patients who had 0% of Ph+ metaphase.

Time frame:
Month 6 and 12
Reported as:
Count of participants · Participants
Percentage of Participants With Complete Cytogenetic Response (CCyR) at Month 6 and 12
ParticipantsNilotinib
Month 689
Month 1284
SecondaryPercentage of Participants With Complete Hematologic Response (CHR) at Month 3, 6, 9, 12, 18 and 24

A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved: WBC \<10 x 109/L, thrombocyte \<450 x 109/L, myelocyte + metamyelocyte \<%5 in blood, no sign of blast and promyelocyte in blood, basophil \<%5, and no sign of extramedullary involvement.

Time frame:
Month 3, 6, 9, 12, 18 and 24
Reported as:
Count of participants · Participants
Percentage of Participants With Complete Hematologic Response (CHR) at Month 3, 6, 9, 12, 18 and 24
ParticipantsNilotinib
Month 3104
Month 6102
Month 9100
Month 1296
Month 1893
Month 2492
SecondaryTime to Major Molecular Response (MMR)

Time to MMR is defined as the time period from the date of first dose intake until the first documented MMR.

Time frame:
24 months
Reported as:
Mean · days
Time to Major Molecular Response (MMR)
daysNilotinib
Time to Major Molecular Response (MMR)252.38 ± 153.22
SecondaryDuration of Major Molecular Response (MMR)

MMR duration is defined as the time from the date of first documented MMR to the first time of the lost MMR, progression or death.

Time frame:
24 months
Reported as:
Mean · days
Duration of Major Molecular Response (MMR)
daysNilotinib
Duration of Major Molecular Response (MMR)91 ± 4.22

Adverse events

Collected over Adverse events were collected from the start of the treatment to end of the treatment i.e 24 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib2/112 (1.8%)43/112 (38.4%)90/112 (80.4%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventNilotinib
ThrombocytopeniaBlood and lymphatic system disorders4/112
Chest PainCardiac disorders3/112
Arteriogram coronaryInvestigations3/112
NeutropeniaBlood and lymphatic system disorders2/112
Acute myocardial infarctionCardiac disorders2/112
Abdominal painGastrointestinal disorders2/112
Lipase increasedInvestigations2/112
Acute leukaemiaBlood and lymphatic system disorders1/112
Angina unstableCardiac disorders1/112
BradycardiaCardiac disorders1/112
Most frequent other events
Showing 10 of 20
Most frequent other events
EventNilotinib
ThrombocytopeniaBlood and lymphatic system disorders19/112
HyperbilirubinaemiaHepatobiliary disorders17/112
PruritusSkin and subcutaneous tissue disorders16/112
InfluenzaRespiratory, thoracic and mediastinal disorders13/112
RashSkin and subcutaneous tissue disorders13/112
Alanine aminotransferase increasedInvestigations12/112
Blood triglycerides increasedInvestigations11/112
HypercholesterolaemiaHepatobiliary disorders11/112
Blood alkaline phosphatase increasedInvestigations10/112
LeukopeniaBlood and lymphatic system disorders10/112

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nilotinib
Median47 (19 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female49
Male63
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Nilotinib
08

Study locations

13 sites
  • Novartis Investigative Site
    Eskisehir, Meselik 26480, Turkey
  • Novartis Investigative Site
    Istanbul, TUR 34098, Turkey
  • Novartis Investigative Site
    Adana, 01330, Turkey
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Bursa, 16059, Turkey
  • Novartis Investigative Site
    Diyarbakir, 21000, Turkey
  • Novartis Investigative Site
    Gaziantep, 27310, Turkey
  • Novartis Investigative Site
    Istanbul, 34093, Turkey
  • Novartis Investigative Site
    Izmir, 35040, Turkey
  • Novartis Investigative Site
    Izmir, 35340, Turkey
  • Novartis Investigative Site
    Okmeydani, 34370, Turkey
  • Novartis Investigative Site
    Talas / Kayseri, 38039, Turkey
  • Novartis Investigative Site
    Trabzon, 61080, Turkey
09

References and documents

Publications

  • Saydam G, Haznedaroglu IC, Kaynar L, Yavuz AS, Ali R, Guvenc B, Akay OM, Baslar Z, Ozbek U, Sonmez M, Aydin D, Pehlivan M, Undar B, Dagdas S, Ayyildiz O, Akin G, Dag IM, Ilhan O. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up. Hematology. 2018 Dec;23(10):771-777. doi: 10.1080/10245332.2018.1498167. Epub 2018 Jul 11. PubMed 29996726 ↗
  • Saydam G, Haznedaroglu IC, Kaynar L, Yavuz AS, Ali R, Guvenc B, Akay OM, Baslar Z, Ozbek U, Sonmez M, Aydin D, Pehlivan M, Undar B, Dagdas S, Ayyildiz O, Akkaynak DZ, Akin G, Ilhan O. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Hematology. 2018 Feb 27:1-7. doi: 10.1080/10245332.2018.1444919. Online ahead of print. PubMed 29486663 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2011 to primary completion in Aug 2019, 102 months.

Results were first posted in Sep 2020, 1 year 1 month after primary completion.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 102 months is above that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2011
First posted
Jan 11, 2011
StartActual
Jan 25, 2011
Primary completionActual
Aug 1, 2019
CompletionActual
Aug 1, 2019
Results first posted
Sep 1, 2020
Last update
Sep 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01274351
Responsible party
Sponsor
First posted
Jan 11, 2011
Start date
Jan 25, 2011
Primary completion
Aug 1, 2019
Completion
Aug 1, 2019
Results posted
Sep 1, 2020
Last update
Sep 1, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion